Condition: Acute Spinal Cord Injury (SCI) · Spinal Cord Diseases · Central Nervous System Diseases · Sponsor: NovaGo Therapeutics AG
This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI. The trial will evaluate the safety, tolerability, and PK of 4 dose regimens of NG004, and will evaluate the maximum tolerated dose of NG004.
This description comes directly from the study's public registry record.
Director of Clinical Research · +41433005263 · clinical@novagotx.com
Always discuss trial participation with your own doctor first.
| Klinik für Querschnittgelähmte, Klinikum Bayreuth | Bayreuth, Germany | Recruiting |
| Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, BG Klinikum Bergmannstrost | Halle, Germany | Not Yet Recruiting |
| Klinik für Paraplegiologie, Universitätsklinikum Heidelberg | Heidelberg, Germany | Recruiting |
| Zentrum für Rückenmarksverletzte, Unfallklinik Murnau | Murnau am Staffelsee, Germany | Recruiting |
| Swiss Paraplegic Centre | Nottwil, Switzerland | Recruiting |
| Universitätsklinik Balgrist | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06817577